Wednesday, March 29, 2023


Biotechnology News Magazine

Unravel Biosciences Reports Positive Feedback from FDA Pre-Ind Meeting on RVL001 RETT Syndrome Program

Latest Posts

Risk From Pharma Reps Using Unapproved Content and Messaging in the Field Persists, but a Focus on Training Could Be the Answer

ACTO advises Study Reveals 50% of respondents in leadership roles catch incidents of field reps using unapproved content, but a continuous learning culture could eliminate this behavior.

Entrinsic Bioscience® Expands enterade® Brand with Innovative Approach to the Dietary Support of Irritable Bowel Syndrome with Diarrhea (IBS-D

enterade® IBS-D is the first medical food formulated with plant-based amino acids and electrolytes for Irritable Bowel Syndrome with Diarrhea (IBS-D)-

Russell Finex Helps Leading Pharmaceutical Company Meet High Levels Of Demand With The Russell Compact Sieve

To ensure the highest quality final product, the company reached out to Russell Finex for a high-capacity vibrating screen. After assessing the company’s requirements, Russell Finex recommended the Russell Compact Sieve® as the ideal solution for check-screening pharmaceutical powders due to its stainless-steel contact parts, and easy-to-clean strip down design.

How Biotech Businesses Can Benefit from Freelance Experts

Ashmita Das, CEO of open talent platform Kolabtree, shares some of Kolabtree freelancer’s success stories.

Unravel Biosciences, Inc., (“Unravel”), a therapeutics company that leverages a machine-learned model of human health to advance drugs for complex diseases, today announced the successful completion of its Type B pre-IND meeting with the U.S. Food and Drug Administration (FDA) for its RVL001 program in Rett Syndrome.

The FDA provided written responses to Unravel regarding its proposed proof of concept study for RVL001, a promising therapeutic identified by Unravel’s proprietary drug prediction platform as potentially beneficial for patients with Rett Syndrome via a previously undrugged target. Unravel believes the written response provides clear guidance for RVL001 IND filing and initiation of its proof-of-concept study in Rett syndrome patients later this year.

“We are pleased to have received positive feedback from FDA on our proposed RVL001 clinical study in Rett Syndrome,” said Richard Novak, Ph.D., Unravel Bioscience Co-Founder and CEO. “The successful completion of this key development milestone provides a great validation of Unravel’s ability to rapidly move promising therapies into the clinic, much faster than most conventional approaches to drug development.”

Rett Syndrome is a rare, X-linked neurological disorder occurring primarily in females, starting in early childhood and leading to debilitating cognitive, motor and autonomic disability. With an incidence of one in every 10,000 to 15,000 female births, Rett Syndrome is an orphan disease with no current FDA-approved treatments. Unravel’s proprietary drug discovery platform has identified RVL001 as a promising therapeutic for Rett Syndrome, as well as RVL002, a novel small molecule therapeutic currently being developed.


Latest Posts

Learn More




Our Sister Publication

Medical Device News Magazine